Differential response in patients with large cell neuroendocrine carcinoma of the lung to initial therapy: A case series

Abstract

Abstract Background Large cell neuroendocrine tumors of the lung (LCNEC) are rare. Chemotherapy with the small cell lung carcinoma (SCLC) regimen is the most appropriate treatment for LCNEC. However, there is evidence that the non‐small cell lung cancer regimen is also effective in some reported cases. Due to the differences in response to LCNEC treatment, a standard of care for LCNEC has not been established. Cases The clinical records of nine patients with LCNEC who were treated with anticancer drugs based on an SCLC regimen from March 2016 to March 2022 were retrospectively reviewed. The patients who responded to treatment after one cycle of systemic chemotherapy were compared to those who did not respond. All patients in the responder group had a performance status (PS) of 0 or 1. However, 5 of the 6 patients in the non‐responder group had a PS of 2 or 3, indicating that many patients were in poor general condition. Although patients with multiple metastases to more than one organ prior to treatment were not identified in the responder group, five of these patients were in the non‐responder group. In the non‐responder group, all patients discontinued treatment due to deterioration of general condition during first‐line treatment. Thus, none of them were able to start the second‐line treatment. Conclusion The results of this study may suggest that early diagnosis and initiation of treatment before multiple organ metastasis development and PS decline may have clinical implications that could lead to improved treatment response in patients with LCNEC.

Keywords

• chemotherapy
• large cell neuroendocrine carcinoma
• non‐small cell lung cancer
• small cell lung carcinoma
• treatment